X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
mAbxience will leverage its expertise in biosimilar development to develop and produce the biosimilar product currently in development for the treatment of multiple oncology indications.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 04, 2024
Details:
Through the agreement, mAbxience will be responsible for the manufacture of the active ingredient, developed by Biosidus as a biosimilar of Fabrazyme (agalsidase beta), which will be used for the treatment of Fabry disease.
Lead Product(s): Agalsidase Beta
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biosidus S.A.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 05, 2024
Details:
Under the agreement, Intas receives exclusive rights to commercialise Etanercept biosimilars, through its affiliates, for the treatment of various autoimmune diseases, in more than 150 countries across the globe, including Europe and the United States of America.
Lead Product(s): Etanercept
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Intas Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 20, 2023
Details:
Under the terms of agreement, mAbxience will fully develop the biosimilar, Denosumab (ref Prolia and XGEVA) and manufacture in it's GMP-approved facilities, while Amneal will guide the product through regulatory approval and have exclusive commercialization rights in the US.
Lead Product(s): Denosumab
Therapeutic Area: Musculoskeletal Product Name: MB-09
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amneal Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 12, 2023
Details:
Under the agreemeent, Abbott will commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa, and mAbxience will develop, manufacture and supply the biosimilar molecules.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Abbott Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 20, 2023
Details:
mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (rituximab), through its in-house biosimilars programs and through its investment in mAbxience, Fresenius expects rapid growth in biopharmaceutical market.
Lead Product(s): Rituximab
Therapeutic Area: Oncology Product Name: Novex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fresenius Kabi AG
Deal Size: $553.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 01, 2022
Details:
U.S.FDA has approved Company’s Biologics License Application for bevacizumab-maly, is a vascular endothelial growth factor inhibitor, a biosimilar referencing Avastin for first or second-line treatment metastatic colorectal cancer.
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Alymsys
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amneal Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022
Details:
mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (Rituximab), through its in-house biosimilars programs and through its investment in mAbxience Fresenius expects rapid growth in biopharmaceutical market.
Lead Product(s): Rituximab,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Novex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fresenius Kabi AG
Deal Size: $553.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 31, 2022
Details:
Alymsys (bevacizumab-maly) is a vascular endothelial growth factor inhibitor for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.
Lead Product(s): Bevacizumab-maly,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Alymsys
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Zentiva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
